Financial Results for Q3 FY2017 (April 1 to December 31, 2017)

from the beginning

Financial Results for Q3 FY2017(April 1 to December 31, 2017)

Financial Results for Q3 FY2017

• Financial Results for Q3 FY2017 (Apr.-Dec.)

• Sales of Major Products in Japan

• Sales of Major Products in North America & China

• Segment Information

• Ordinary income & Net income attributable to owners of the parent

Financial Forecasts for FY2017

• Financial Forecasts for FY2017

• Revision of Dividend Forecast

Clinical Development Status

• Development Pipeline (1) (Psychiatry & Neurology Area) (as of January 30, 2018)

• Development Pipeline (2) (Oncology Area) (as of January 30, 2018)

• Development Pipeline (3) (Oncology & Other Areas) (as of January 30, 2018)

• Clinical Development Status (Major changes since October 30, 2017)

• Apomorphine: Phase 3 Topline Data (CTH-300 study)

• Profile of DSP-0509

Appendices

• Changes from Q3 FY2017

• Net Sales by Segment

• Napabucasin - Clinical development progress (as of January 30, 2018)

• Amcasertib, Napabucasin - Clinical development progress (as of January 30, 2018)

• LATUDA (lurasidone) - Clinical development progress (as of January 30, 2018)

• Submission Target of Key Late-stage Pipeline (as of January 2018)

• Product Launch Plan (as of January 2018)

• Disclaimer Regarding Forward-looking Statements

@

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6

• Q&A 7